Skip to main content
Triangle logo TriangleGet started

NX-5948 (NCT07221500)

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201): a one-minute explainerNCT072215001 min

NX-5948 trial for Chronic Lymphocytic Leukemia (CLL) (NCT07221500). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma requiring treatment. Previous therapy must include both covalent and non-covalent BTK inhibitors, plus a BCL-2 inhibitor.

The idea: daily oral NX-5948 breaks down the BTK protein. Everyone receives it in continuous 28-day cycles. Researchers assess responses, safety and drug levels over time. Prior BTK-degrader treatment excludes participation.

This phase 2 study plans 100 patients. Nurix sponsors it; 27 US sites are recruiting, including Phoenix.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.